** Shares of biotech firm Humacyte HUMA.O down 23.5% to $2.20 post-market after stock offering news
** Durham, North Carolina-based firm announces proposed stock offering without disclosing deal size
** Co intends to use net offering proceeds to fund commercialization of its implant Symvess for patients with extreme blood vessel injury
** TD Cowen, Barclays and BTIG jt bookrunners
** With ~122.65 mln shares outstanding, co has ~$353 mln market cap, per LSEG data
** HUMA shares finished Tuesday's session down 13.4% at $2.88. YTD, stock down 43%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。